
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

FORM 8-K

**CURRENT REPORT
Pursuant to Section 13 or 15(D)
of the Securities Exchange Act of 1934**

November 9, 2018

Date of report (Date of earliest event reported)

Axsome Therapeutics, Inc.
(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction
of incorporation)

001-37635
(Commission
File Number)

45-4241907
(IRS Employer
Identification No.)

25 Broadway, 9th Floor
New York, New York
(Address of principal executive offices)

10004
(Zip Code)

Registrant's telephone number, including area code **(212) 332-3241**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x

Item 8.01 Other Events

On November 9, 2018, Axsome Therapeutics, Inc. updated its presentation slide deck. Attached as Exhibit 99.1 to this Current Report on Form 8-K is a copy of the presentation slide deck.

Item 9.01 Financial Statements and Exhibits.**(d) Exhibits.**

<u>Exhibit Number</u>	<u>Description</u>
99.1	Corporate Presentation.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Axsome Therapeutics, Inc.

Dated: November 9, 2018

By: /s/ Herriot Tabuteau, M.D.
Name: Herriot Tabuteau, M.D.
Title: President and Chief Executive Officer

 NASDAQ: AXSM

AXSOME

THERAPEUTICS

November 2018

© Axsome Therapeutics, Inc.



Forward-Looking Statements & Safe Harbor

Certain information contained in this presentation may include "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as "predicts," "believes," "potential," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. In particular, the Company's statements regarding trends and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the success, timing and cost of our ongoing clinical trials and anticipated clinical trials for our current product candidates, including statements regarding the timing of initiation and completion of the trials, interim analyses and receipt of interim results; the timing of and our ability to obtain and maintain U.S. Food and Drug Administration or other regulatory authority approval of, or other action with respect to, our product candidates; the Company's ability to obtain additional capital necessary to fund its operations; the Company's ability to generate revenues in the future; the Company's ability to successfully defend its intellectual property or obtain the necessary licenses at a cost acceptable to the Company, if at all; the successful implementation of the Company's research and development programs; the enforceability of the Company's license agreements; the acceptance by the market of the Company's product candidates, if approved; and other factors, including general economic conditions and regulatory developments, not within the Company's control. These factors could cause actual results and developments to be materially different from those expressed in or implied by such statements. Forward-looking statements are not guarantees of future performance, and actual results may differ materially from those projected. The forward-looking statements are made only as of the date of this presentation and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance.

This presentation also contains estimates and other statistical data made by independent parties and by us relating to market size and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. Neither we nor any other person makes any representation as to the accuracy or completeness of such data or undertakes any obligation to update such data after the date of this presentation. In addition, these projections, assumptions and estimates are necessarily subject to a high degree of uncertainty and risk.

Developing novel therapies for CNS disorders.

Axsome is addressing growing markets, where current treatment options are limited or inadequate, by leveraging well-characterized compounds to create novel therapeutics to meet unmet medical needs and improve the lives of patients.

Our Technologies

Enabling new and innovative medicines to treat CNS conditions



Chiral &
Formulation
Chemistry



MoSEIC™
Delivery



Metabolic
Inhibition



Chemical
Synthesis &
Analysis

Our CNS Candidates and Pipeline

- Four differentiated clinical-stage CNS assets targeting significant and growing markets.
- Patent protection to 2034-2036, worldwide rights.

Product Candidate	Preclinical	Phase 1	Phase 2	Phase 3
AXS-05 (DM + BUP)	Treatment Resistant Depression: Fast Track Granted			Ongoing
	Agitation in Alzheimer's Disease: Fast Track Granted			Ongoing
	Major Depressive Disorder			Ongoing
	Smoking Cessation			Ongoing
AXS-07 (MoSEB™ Mx + Riz)	Migraine			
AXS-12 (Reboxetine)	Narcolepsy; U.S. Orphan Designation			
AXS-09 (DM + S-BUP)	CNS Disorders			

Abbreviations: BUP = Bupropion; CNS = Central Nervous System; DM = Dextromethorphan; Mx = Meloxicam; Riz = Rizatriptan; S-BUP = Esbupropion.

Axsome PPC Candidates and Pipeline

- Two differentiated clinical-stage pain and primary care assets targeting significant and growing markets.
- Patent protection to 2034, worldwide rights.

Product Candidate	Preclinical	Phase 1	Phase 2	Phase 3
AXS-02 (DZT)	Knee OA with BMLs: SPA Received; Fast Track Granted			Ongoing
	CLBP with MCs			
AXS-06 (MoSEB™ Mx + Eso)	OA and RA			

Abbreviations: BML = Bone Marrow Lesions; CLBP = Chronic Low Back Pain; DZT = Disodium Zoledronate Tetrahydrate; Eso = Esomeprazole; MC = Modic Changes; Mx = Meloxicam; OA = Osteoarthritis; RA = Rheumatoid Arthritis; SPA = Special Protocol Assessment

AXS-05

Dextromethorphan (DM) + Bupropion (BUP)

Novel therapy for CNS
disorders:

- Treatment Resistant Depression (TRD)
- Agitation in Alzheimer's Disease (AD)
- Major Depressive Disorder (MDD)
- Smoking Cessation



CNS Disorders: Mechanisms of Action

Pharmacodynamic Synergy

Mechanism of Action	AXS-05		
	DM	BUP	DM+BUP
NMDA Receptor Antagonist	✓		✓
Sigma-1R Agonist	✓		✓
Norepinephrine Reuptake Inhibitor	✓	✓	✓
Serotonin Reuptake Inhibitor	✓		✓
Dopamine Reuptake Inhibitor		✓	✓
Nicotinic ACh Receptor Antagonist	✓	✓	✓

DM = Dextromethorphan; BUP = Bupropion.

✓ Present

CNS Disorders: Mechanisms of Action

Mechanism of Action	Pharmacodynamic Synergy			Relevant Indications								Related Agents
	DM	BUP	AXS-05 DM+BUP	ADHD	Anxiety	Alzheimer's	Depression	Fibromyalgia	OCD	Pain	Smoking cessation	
NMDA Receptor Antagonist	✓		✓									<ul style="list-style-type: none"> • Ketamine • Memantine (Namenda®)
Sigma-1R Agonist	✓		✓									<ul style="list-style-type: none"> • Fluvoxamine (Luvox®) • Donepezil (Aricept®)
Norepinephrine Reuptake Inhibitor	✓	✓	✓									<ul style="list-style-type: none"> • Duloxetine (Cymbalta®) • Venlafaxine (Effexor®)
Serotonin Reuptake Inhibitor	✓		✓									<ul style="list-style-type: none"> • Escitalopram (Lexapro®) • Fluoxetine (Prozac®) • Sertraline (Zoloft®)
Dopamine Reuptake Inhibitor		✓	✓									<ul style="list-style-type: none"> • Bupropion (Wellbutrin®)
Nicotinic ACh Receptor Antagonist	✓	✓	✓									<ul style="list-style-type: none"> • Bupropion (Wellbutrin®)


DM = Dextromethorphan; BUP = Bupropion. ✓ Present

☐ Relevant


1. Indications listed are associated with the mechanism of action and are not related to either DM or BUP, unless specifically noted.
2. Agents do not contain DM or BUP, unless specifically noted.

CNS Disorders: Novel Therapy for CNS Disorders

DM Alone



AXS-05




DM = Dextromethorphan; DXO = Dextrorphan; BUP = Bupropion.

- Phase 1 trials with AXS-05 completed:
 - Significant increase in DM plasma levels.
- Phase 3 trials in TRD and AD Agitation initiated.
- Phase 2 trials in MDD and Smoking Cessation initiated.

IP Overview

- 33 issued patents – protection through 2034.

CNS Disorders: Phase 1 Results



DM concentrations associated with reported therapeutic responses shown (dotted lines).

* DM plasma concentrations reported with dose (DM 30 mg + Q 10 mg) resulting in reduction of agitation symptoms in AD patients, and of depressive symptoms in AD and PBA patients.

† DM plasma concentrations reported with dose (DM 20 mg + Q 10 mg) resulting in reduction in emotional symptoms in PBA patients.

Axsome data on file.

Therapeutic DM concentrations from NDA 021879, FDA Clinical Pharmacology Review.

DM, Dextromethorphan; Q, Quinidine; BUP, Bupropion; AD, Alzheimer's disease; PBA, pseudobulbar affect

CNS Disorders: TRD Overview

- 63% and 44% of MDD patients have inadequate response to initial therapy and second line therapy, respectively.²
- Only 1 approved drug for TRD = unmet medical need.
- AXS-05 combines the MOA of 4 distinct anti-depressant drug classes into one novel oral therapeutic.
- DM antidepressant effects demonstrated preclinically and clinically.
- Phase 3 interim futility analysis: IDMC recommended trial continuation.
- Phase 2 MDD trial ongoing.



3M patients
in the U.S.¹⁻³

Product Candidate	Preclinical	Phase 1	Phase 2	Phase 3
AXS-05 (DM + BUP)	Treatment Resistant Depression: Fast Track Granted			Ongoing
	Major Depressive Disorder			Ongoing

Abbreviations: DM = Dextromethorphan; BUP = Bupropion.


1. Marcus SC, Olfson M. *Arch Gen Psychiatry* 2010;67:1265-1273.

2. Rush AJ, et al. *Am J Psychiatry* 2006;163:1905-1917.

3. U.S. Census Bureau, Population April 1, 2010 to July 1, 2013.

CNS Disorders: TRD Clinical Rationale


Symptom Reduction in TRD Patients Treated with DM and Metabolic Inhibitor¹



- Failed 2 to 10 prior treatments
 - 45% of patients had ≥ 50% reduction in MADRS
- ** P<0.01 versus baseline

1. Murrough J, et al. *J Affect Disord.* 2017;218:277-283.
 2. Cummings J, et al. *JAMA.* 2015;314:1242-1254.

Depressive Symptom Reduction in AD Agitation Patients Treated with DM and Metabolic Inhibitor²




CNS Disorders:

TRD Phase 3 Design



A Phase 3 trial to assess the efficacy and safety of AXS-05 in the treatment of TRD.



BUP = Bupropion; DM = Dextromethorphan.

- **Primary Endpoint:** Change in depression score from randomization to end of study, measured using the Montgomery-Asberg Depression Rating Scale (MADRS).
- **Key Inclusion Criteria:**
 - Male or female 18-65 years old
 - History of inadequate response to 1 or 2 adequate antidepressant treatments
- Interim futility analysis: Conducted in April 2018. IDMC recommended trial continuation.

AXSOME THERAPEUTICS


© Axsome Therapeutics, Inc.

14

CNS Disorders:

Agitation in AD Overview

- Agitation and aggression seen in approximately 45% of AD patients during 5-year period.³
- Characterized by emotional distress, aggressive behaviors, disruptive irritability, disinhibition, and caregiver burden.⁴
- Associated with^{4,5}:
 - Accelerated cognitive decline
 - Earlier nursing home placement
 - Increased mortality
- No approved medication = unmet medical need.
- Proof of concept: DM plus metabolic inhibitor reduced agitation in AD patients.
- Phase 2/3 ongoing.



2M patients
in the U.S.^{1,2}

Product Candidate	Preclinical	Phase 1	Phase 2	Phase 3
AXS-05 (DM + BUP)	Agitation in Alzheimer's Disease: Fast Track Granted			Ongoing

Abbreviations: DM = Dextromethorphan; BUP = Bupropion.

1. Ryu, SH, et al. *Am J Geriatr Psychiatry*. 2005;13:976-983.

2. Hebert, LE, et al. *Neurology*. 2013;80:1778-1783.

3. Steinberg M, et al. *Int J Geriatr Psychiatry*. 2008;23:170-177.

4. Antonisdottir IM, et al. *Expert Opin Pharmacother*. 2015;11:1649-1656.


5. Rabins PV et al. *Alzheimers Dement*. 2013; 9:204-207.

CNS Disorders:

Agitation in AD Clinical Rationale

- Randomized, double-blind, placebo-controlled, two-stage trial.
 - Placebo (n=125), 30 mg DM + 10 mg quinidine (Q) (n=93), for stage 1.
- DM+Q treatment reduced agitation/aggression in AD by 46% vs. 24% for placebo ($P<0.001$)—primary endpoint.
- Statistically significant improvement in multiple secondary endpoints.
- DM plasma levels achieved with AXS-05 in target therapeutic range.
- Potential for additional contribution from bupropion component of AXS-05.

Change in Agitation/Aggression Scores in AD with DM and Metabolic Inhibitor Quinidine (Q)



Cummings J, et al. *JAMA*. 2015;314:1242-1254.


CNS Disorders:

Agitation in AD Phase 2/3 Design



**ADVANCE
STUDY**

A Phase 2/3 trial to assess the efficacy and safety of
AXS-05 in the treatment of Agitation in AD.



BUP = Bupropion; DM = Dextromethorphan.

- **Primary Endpoint:** Cohen-Mansfield Agitation Inventory (CMAI).
- **Key Inclusion Criteria:**
 - Diagnosis of probable Alzheimer's disease
 - Clinically significant agitation
- Interim futility analysis: Planned at approximately 30% target randomized subjects.
- Interim efficacy analysis: Planned at approximately 60% target randomized subjects.

AXSOME THERAPEUTICS

© Axsome Therapeutics, Inc.

17

CNS Disorders:

Smoking Cessation Overview

- Smoking is single largest cause of preventable death in the U.S.¹
- 70% of smokers want to quit and only 3-5% who attempt to quit without assistance are successful for 6-12 months.²
- DM component of AXS-05 significantly reduced nicotine self-administration in nicotine-dependent rats.
- Bupropion component of AXS-05 has been found to be effective for smoking cessation in clinical trials.
- Axsome entered into a research collaboration with Duke University to evaluate AXS-05 in a Phase 2 clinical trial in smokers attempting to quit.
- Phase 2 trial ongoing.



40M patients
in the U.S.¹

Product Candidate	Preclinical	Phase 1	Phase 2	Phase 3
AXS-05 (DM + BUP)	Smoking Cessation			Ongoing

Abbreviations: DM = Dextromethorphan; BUP = Bupropion.

1. U.S. Department of Health and Human Services. The Health Consequences of Smoking: 50 Years of Progress. A Report of the Surgeon General. 2014.

2. Hughes JR, et al. *Addiction*. 2004;99(1):29-38.

AXSOME THERAPEUTICS

© Axsome Therapeutics, Inc.

18

AXS-07

**MoSEIC™ Meloxicam +
Rizatriptan**

Novel therapy for:

- Migraine



AXSOME THERAPEUTICS

© Axsome Therapeutics, Inc.

19

AXS-07: MoSEIC™ Meloxicam + Rizatriptan for Migraine

- Meloxicam is a new molecule for migraine—not currently approved or used for this indication due to prolonged T_{max}
- MoSEIC delivery enables its use in abortive treatment of migraine
 - Rapid T_{max} of MoSEIC meloxicam is ideal for migraine treatment
 - Extended half-life of MoSEIC meloxicam should lead to lower symptom recurrence
- AXS-07 combines unique PK of MoSEIC meloxicam with proven efficacy of rizatriptan
- FDA Pre-IND written guidance received
- Phase 3 initiation anticipated in 4Q 2018 – 1Q 2019





37M patients
in the U.S.¹

Product Candidate	Preclinical	Phase 1	Phase 2	Phase 3
AXS-07 (MoSEIC™ Mx + Riz)	Migraine			

Abbreviations: Mx = Meloxicam; Riz = Rizatriptan.

1. Pleis JR, et al., *Summary health statistics for U.S. adults: National Health Interview Survey, 2009. National Center for Health Statistics. Vital Health Stat 10(249). 2010.*

Migraine: MoSEIC™ Meloxicam Phase 1 Results



- MoSEIC meloxicam T_{max} 9 times faster than Mobic® (0.5 hour versus 4.5 hours, respectively, $p < 0.0001$).
- Therapeutic plasma levels achieved within 15 minutes of oral dosing of MoSEIC meloxicam.
- MoSEIC meloxicam had higher mean C_{max} ($p = 0.0018$), faster time to therapeutic plasma concentration ($p < 0.0001$), and time to half-maximal plasma concentration ($p < 0.0001$) as compared to Mobic®.
- Terminal half-lives were approximately 20 hours for MoSEIC meloxicam and 22 hours for Mobic®.

Sources: Axsome data on file. IV and IM data from Euler-Ziegler et al., *Inflamm Res* 50, Supplement 1 (2001) S5-S9.

AXSOME THERAPEUTICS

© Axsome Therapeutics, Inc.

21

AXS-07: Differentiated Clinical Profile for **Migraine**



Rapid absorption & onset of action

Based on rapid absorption of MoSEIC meloxicam and expected additive effect of AXS-07 components



Strong & consistent pain relief

Potential for superior efficacy as compared to current treatments based on expected additive effect of AXS-07 components



Sustained pain relief

Based on extended MoSEIC meloxicam half-life and expected additive effect of AXS-07 components



Pharmaco- economic benefits

Potentially superior efficacy expected to result in reduced use of medication and medical services, reduced absenteeism and loss of productivity

AXS-12

Reboxetine

Novel therapy for:

- Narcolepsy



CNS Disorders: Narcolepsy Overview

- Debilitating sleep disorder characterized by excessive daytime sleepiness (EDS) and cataplexy.
- Limited treatment options
 - All current approved drugs are scheduled
 - Only one approved agent for cataplexy.
- AXS-12 showed potent activity in genetic mouse model of narcolepsy, and positive effects in human pilot trial in narcolepsy patients.
- Phase 2 start anticipated 4Q 2018 with data readout estimated 1H 2019.
- U.S. Orphan Drug Designation.




Orphan Disease
185,000 patients
in the U.S.

Product Candidate	Preclinical	Phase 1	Phase 2	Phase 3
AXS-12 (Reboxetine)	Narcolepsy; U.S. Orphan Designation			

CNS Disorders:


Narcolepsy Scientific Rationale



- Reboxetine dose-dependently reduced the number of narcoleptic episodes in hypocretin (orexin)-deficient mice ($P < 0.0001$)

Adapted from Schmidt et al. *Behav Brain Res.* 2016 Jul 15;308:205-10.

Barriers to Entry



Our Team

Management

Herriot Tabuteau, MD
 Founder & CEO

Nick Pizzie, CPA, MBA
 CFO

Cedric O’Gorman, MD, MBA
 SVP, Clinical Development &
 Medical Affairs

Mark Jacobson, MA
 SVP, Operations



A Member of the Roche Group



Board of Directors

Roger Jeffs, PhD
 Former President, Co-CEO, Director
United Therapeutics Corp.
 Prior positions at Amgen and Burroughs
 Wellcome

Myrtle Potter
 Former President, COO
Genentech
 Prior positions at Bristol-Myers Squibb and
 Merck

Mark Saad
 Former CFO
Bird Rock Bio, Inc.
 Former COO of the Global Healthcare
 Group at UBS

Mark Coleman, MD
 Medical Director
National Spine and Pain Centers
 Diplomat of the American Board of
 Anesthesiology

Herriot Tabuteau, MD
 Chairman

Key Financial Information

	As of September 30, 2018
Cash (Pro-Forma) ¹ :	\$23.0 Million
Debt (Face Value) ² :	\$7.7 Million
Common Shares Outstanding (Pro-Forma) ¹ :	29.4 Million
Options and Warrants Outstanding ³ :	4.8 Million

- **Financial guidance:** Cash anticipated to fund operating requirements into the first quarter of 2020.

1. Includes the effect of the Registered Direct Offering which closed in October 2018.

2. Book value of \$7.2 million.

3. Consists of 2.7 million options and 2.1 million warrants.

Clinical Milestones

Product Candidate	Indication	2018	2019
AXS-05 (DM + BUP)	TRD	✓ STRIDE-1 interim analysis	● STRIDE-1 top-line results (1Q 2019)
	AD Agitation	● ADVANCE-1 interim analysis (4Q 2018)	● ADVANCE-1 interim efficacy analysis ● ADVANCE-1 top-line results (2H 2019/1H 2020)
	MDD	✓ Ph 2 trial start ● Ph 2 top-line results (Year end 2018)	
	Smoking Cessation	✓ Ph 2 trial start	● Ph 2 top-line results (1Q 2019)
AXS-07 (MoSEIC™ Mx + Riz)	Migraine	● Ph 3 trial start (4Q 2018 – 1Q 2019)	● Ph 3 top-line results
AXS-12 (Reboxefine)	Narcolepsy	● Ph 2 trial start (4Q 2018)	● Ph 2 top-line results (1H 2019)

Abbreviations: AD= Alzheimer's Disease; BUP = Bupropion; DM = Dextromethorphan; MDD = Major Depressive Disorder; Mx = Meloxicam; Riz = Rizatriptan; TRD = Treatment Resistant Depression.

✓ Accomplished milestone.

● Upcoming milestone.

AXSOME

THERAPEUTICS

Thank you.

For more information, please contact

Mark Jacobson
SVP, Operations

212-332-3243
mjacobson@Axsome.com

axsome.com



APPENDIX – AXSOME PPC

Axsome PPC Candidates and Pipeline

- Two differentiated clinical-stage pain and primary care assets targeting significant and growing markets.
- Patent protection to 2034, worldwide rights.

Product Candidate	Preclinical	Phase 1	Phase 2	Phase 3
AXS-02 (DZT)	Knee OA with BMLs: SPA Received; Fast Track Granted			Ongoing
	CLBP with MCs			
AXS-06 (MoSEB™ Mx + Eso)	OA and RA			


Abbreviations: BML = Bone Marrow Lesions; CLBP = Chronic Low Back Pain; DZT = Disodium Zoledronate Tetrahydrate; Eso = Esomeprazole; MC = Modic Changes; Mx = Meloxicam; OA = Osteoarthritis; RA = Rheumatoid Arthritis; SPA = Special Protocol Assessment

AXS-02

Disodium Zoledronate Tetrahydrate

Novel therapy for chronic pain:

- Knee Osteoarthritis (OA) with Bone Marrow Lesions (BMLs)
- Chronic Low Back Pain (CLBP) with Modic Changes (MCs)



Chronic Pain: Differentiated Therapy



Mechanisms of Action


Inhibits
bone-resorbing
osteoclasts


Downregulates
acid-sensing[†]
ion channels



Reduces
pro-inflammatory
cytokine production


Anti-angiogenic

[†]Acid is a well known cause of pain.

Chronic Pain: Knee OA with BMLs Overview

- Bone marrow lesions (BMLs) on MRI are associated with pain in knee osteoarthritis (OA).¹
- BMLs are regions of increased bone turnover, and reduced mineral density.^{2,3}
- Zoledronic acid inhibits bone resorption and increases mineral density.
- Phase 3 trial initiated based on positive Phase 2 results with IV zoledronic acid.
- Phase 3 interim analysis: IDMC recommended continuation to full enrollment



7M patients
in the U.S.⁴⁻⁹

Product Candidate	Preclinical	Phase 1	Phase 2	Phase 3
AXS-02 (DZT)	Knee OA with BMLs: SPA Received; Fast Track Granted			Initiated

Abbreviations: DZT = Disodium Zoledronate Tetrahydrate.

* MRI showing BML in medial tibia from Driban, et al. *Arthritis Res Ther.* 2013;15:R112.

1. Driban JB, et al. *Arthritis Res Ther.* 2013;15:R112.

2. Hunter DJ, et al. *Arthritis Res Ther.* 2009;11:R11.

3. Kazakia GJ, et al. *Osteoarthritis Cartilage.* 2013;21:94-101.

4. Lawrence RC, et al. *Arthritis Rheum.* 2008;58:26-35.

AXSOME THERAPEUTICS

5. Zhang Y, Jordan. *JM Clin Geriatr Med.* 2010;26:355-69.

6. Tanamas SK, et al. *Rheumatology.* 2010;49:2413-19.

7. Guermazi A, et al. *BMJ.* 2012;345:e5339.

8. Jensen OK, et al. *Spine J.* Feb. 14, 2014; pii:S1529-9430(14)00214-9.

9. U.S. Census Bureau, Population April 1, 2010 to July 1, 2013.


Chronic Pain: Knee OA with BMLs Phase 3 Design

coast-1

Clinical Knee OA Symptom
Treatment 1 Study

Special Protocol
Assessment (SPA)
received


A Phase 3 trial to assess the efficacy and safety of
AXS-02 in the treatment of pain of knee OA associated with BMLs.



- **Primary Endpoint:** Change in pain intensity from baseline to week 24, measured using the 0-10 Numerical Rating Scale (NRS).
- **Key Inclusion Criteria:**
 - Male at least 50 years of age or postmenopausal female, with knee OA and BMLs
 - Moderate or worse knee pain
- **Dosage:** Once per week for six weeks; no drug for remainder of double-blind phase.

Chronic Pain: CLBP with MCs Overview

- Modic changes (MCs) type 1 (M1) on MRI are associated with chronic low back pain (CLBP).¹
- Increased bone turnover on bone scan is seen in M1 lesions.²
- Increased pro-inflammatory cytokines, and vascular density seen in M1 lesions.³
- Zoledronic acid reduces bone turnover, suppresses the production of inflammatory mediators, and is anti-angiogenic.
- Phase 2 results: Zoledronic acid reduced pain in patients with CLBP.
- FDA clearance received for IND for Phase 3 trial – initiation planned following readouts from CREATE-1 and STRIDE-1.
- Issued U.S. patents: protection into 2034 – uses of oral zoledronic acid for low back pain.



1.6M patients
in the U.S.⁴⁻⁷

Product Candidate	Preclinical	Phase 1	Phase 2	Phase 3
AXS-02 (DZT)	CLBP with MCs			

Abbreviations: DZT = Disodium Zoledronate Tetrahydrate.

* MRI showing modic type 1 lesions from Luoma K, et al. *European Congress of Radiology (ECR)*. 2014;Poster B-0458.

1. Zhang Y, et al. *Eur Spine J*. 2008;17:1289-1299.

2. Järvinen J, et al. *Spine: ISSLS Society Meeting Abstracts*. Oct. 2011;Volume Suppl, Abstract GP127.

3. Rahme R, Moussa R. *Am J Neuroradiol*. 2008;29:838-42.

4. Lawrence RC, et al. *Arthritis Rheum*. 2008;58:26-35.

5. Zhang Y, Jordan. *JM Clin Geriatr Med*. 2010;26:355-69.

6. Jensen OK, et al. *Spine J*. Feb. 14, 2014;pii:S1529-9430(14)00214-9. 7. U.S. Census Bureau, Population April 1, 2010 to July 1, 2013.

AXS-06

MoSEIC™ Meloxicam + Esomeprazole

Novel therapy:

- Osteoarthritis
- Rheumatoid arthritis



OA and RA:

MoSEIC™ Meloxicam Overview

- MoSEIC meloxicam is a potent, oral, rapidly-absorbed, once-daily, non-opioid, COX-2 preferential, pain therapeutic.
- Standard meloxicam has an extended T_{max} (4-6 hours) which delays its onset of action.^{1,2}
- Axsome's MoSEIC (Molecular Solubility Enhanced Inclusion Complex) technology substantially increases the rate of absorption of meloxicam while maintaining its approximately 20-hour half-life.
- Phase 1 results: 9 times faster T_{max} , higher C_{max} and similar half-life, compared to Mobic®.
- Potential utility for migraine, and the signs and symptoms of OA and RA.
- AXS-06 is a fixed-dose combination of MoSEIC meloxicam and esomeprazole (to reduce risk of NSAID-associated ulcers).

IP Overview

- 5 issued patents and 2 allowed application – protection through 2036.
- Pharmacokinetic patents
- More than 25 U.S. and international applications.

1. Mobic® (meloxicam) FDA Package Insert.

2. Euler-Ziegler et al., *Inflamm Res* 50, Supplement 1 (2001) S5–S9.

AXS-06:**MoSEIC™ Meloxicam + Esomeprazole for OA & RA**

- AXS-06 is a fixed-dose combination of MoSEIC™ meloxicam and esomeprazole
- Being developed to treat OA and RA, and to reduce the risk of NSAID-associated upper GI ulcers
- Potentially best-in-class NSAID profile:
 - Oral administration with IV-like onset of action
 - Long half-life for sustained effect and once-daily dosing
 - Improved GI safety from esomeprazole component
- Positive Phase 1 results: therapeutic meloxicam concentrations within 15 mins, gastroprotective esomeprazole concentrations
- FDA Pre-IND written guidance received
- AXS-06 is Phase 3-ready



120M NSAID TRx
per year
in the U.S.

Product Candidate	Preclinical	Phase 1	Phase 2	Phase 3
AXS-06 (MoSEIC™ Mx + Eso)	OA and RA			Phase 3 ready

Abbreviations: Eso = Esomeprazole; Mx = Meloxicam; OA = Osteoarthritis; RA = Rheumatoid Arthritis.

AXSOME

THERAPEUTICS

Thank you.

axsome.com